Halozyme abandons its €2bn pursuit of Evotec

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations

Pair of R&D updates bolster GSK ahead of investor meeting

GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares

Halozyme abandons cancer R&D as lead drug failed